![](/images/graphics-bg.png)
Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab
Joint Authors
Tao, Chi-Wei
Chen, Shu-Jen
Lapke, Nina
Tan, Kien Thiam
Chen, Mei-Yin
Tseng, Ching-Min
Source
Case Reports in Oncological Medicine
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-03-02
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
For non-small-cell lung cancer (NSCLC) patients without established actionable alterations in genes such as EGFR or ALK, options for targeted therapy remain limited in clinical practice.
About 5% of lung adenocarcinoma patients have tumors with ERBB2 genetic alterations, with even fewer patients harboring ERBB2 amplification.
Currently, clinical trials mainly use IHC, FISH, or mutation testing to identify potential responders to ERBB2-targeting agents.
The use of next-generation sequencing (NGS) to detect ERBB2 alterations, including copy number variants, is rare.
In this study, we present an EGFR- and ALK-negative advanced NSCLC case for which we conducted comprehensive tumor genomic profiling to identify potentially actionable alterations.
The tumor harbored an ERBB2 amplification, and trastuzumab-based therapy resulted in an excellent response, with a necrotic regression of the patient’s lung lesion.
Although he developed brain metastasis four months after trastuzumab initiation, he survived for an additional period of eight months without local recurrence or other systemic metastasis.
This case report shows that the use of comprehensive genetic testing enables the identification of rare actionable alterations in NSCLC patients without other options for targeted treatment.
American Psychological Association (APA)
Tao, Chi-Wei& Chen, Mei-Yin& Tseng, Ching-Min& Lapke, Nina& Chen, Shu-Jen& Tan, Kien Thiam. 2020. Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab. Case Reports in Oncological Medicine،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1149536
Modern Language Association (MLA)
Tao, Chi-Wei…[et al.]. Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab. Case Reports in Oncological Medicine No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1149536
American Medical Association (AMA)
Tao, Chi-Wei& Chen, Mei-Yin& Tseng, Ching-Min& Lapke, Nina& Chen, Shu-Jen& Tan, Kien Thiam. Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab. Case Reports in Oncological Medicine. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1149536
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1149536